Today's Pharma Pulse
Global drugmakers accelerate U.S. manufacturing and R&D amid looming 100% tariff threat
Pharmaceutical giants are boosting U.S. production and research investments as the Trump administration threatens 100% tariffs on branded drugs unless prices are cut or production moves domestically. Companies including Pfizer, AstraZeneca, Eli Lilly, Johnson & Johnson and Roche have pledged commitments ranging from $3.5 billion to $70 billion to secure temporary tariff exemptions.
With Measles Roaring Back, the Search for a Drug Is On
Measles cases surged in 2025, marking the worst U.S. outbreak since 1991 as vaccination rates fell, prompting a sudden wave of biotech interest in therapeutic development. Two U.S. biotech firms have launched antibody trials and another has begun animal testing of an antiviral, while academic labs, including Dr. Dawid Zyla’s, report early promising data. Although no treatments are yet approved and commercial products are years away, the renewed disease burden is creating a potential market that was previously nonexistent.
Locking the Sec61 Gate to Corral Disease
Researchers are developing small‑molecule inhibitors that lock the Sec61 translocon in its closed conformation, preventing pathogenic proteins from entering the endoplasmic reticulum. Pre‑clinical studies show that these blockers can suppress the secretion of pro‑inflammatory cytokines and reduce tumor growth in...
J&J Looks to Widen Imaavy’s Use; $300M Backs Rare Disease Drug Launch
Johnson & Johnson reported that its autoimmune drug Imaavy (nipocalimab) produced durable hemoglobin improvements in a Phase 2/3 trial for warm autoimmune hemolytic anemia (wAIHA), enrolling 115 adults and outperforming placebo at 24 weeks. The data, slated for presentation at the...
Olezarsen Reduces Triglycerides, Acute Pancreatitis Events
Researchers presented pooled data from 455 patients with severe hypertriglyceridemia showing that olezarsen, an antisense drug targeting ApoC‑III, slashed triglyceride levels by up to 65.5% after six months. The treatment also cut the incidence of acute pancreatitis by 85% over...
J&J Adds Rare Disease wAIHA to Imaavy's Potential Uses
Johnson & Johnson announced that its FcRn inhibitor Imaavy (nipocalimab) achieved a significant hemoglobin response in a phase 2/3 ENERGY trial for warm autoimmune hemolytic anemia (wAIHA), a rare disease lacking FDA‑approved treatments. Patients receiving 30 mg/kg showed three‑fold higher response rates...
Claude Fable 5 Quietly Routes Biology & Chemistry Prompts to an Older Model & What That Safety Lockdown Means for...
Anthropic released Claude Fable 5, its first publicly available Mythos‑class model, on June 9 2026. The model embeds safety classifiers that silently reroute biology, chemistry, cybersecurity, and model‑distillation prompts to the older Opus 4.8 engine, causing a pop‑up warning for queries like “mitochondria...
STAT+: Enliven Therapeutics’ Leukemia Drug Shows Promise in New Study
Enliven Therapeutics reported that its targeted drug ELVN-001 achieved a major molecular response in 48% of chronic myeloid leukemia patients after 24 weeks of an 80 mg once‑daily regimen. The early‑stage data compare favorably with Novartis’ blockbuster therapy and an experimental...
Novartis Gets Win for Another Avidity Muscular Dystrophy AOC
Novartis is preparing to discuss regulatory filings for del‑brax, an antibody‑oligonucleotide conjugate that could become the first disease‑modifying therapy for facioscapulohumeral muscular dystrophy (FSHD). In the phase 1/2 FORTITUDE study, del‑brax markedly lowered muscle‑damage biomarkers such as KHDC1L and creatine kinase...
Takeda's $4B TYK2 Drug Outperforms Bristol Myers' Sotyktu
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test https://t.co/aGYIIzQtvG @ByJonGardner $TAK $BMY $ALMS
Precision Hematology Drives Next‑Gen Clinical Trial Design
Precision hematology: Next generation clinical trial design - #EHA2026 #ClinicalTrials #ctsm Simon Richardson #ALLsm https://t.co/zoIuCqaMpG
J&J Reports the P-II/III (ENERGY) Trial Data on Imaavy for Warm Autoimmune Hemolytic Anemia (wAIHA)
Johnson & Johnson presented Phase II/III ENERGY trial data for its monoclonal antibody Imaavy (nipocalimab) in 115 adults with warm autoimmune hemolytic anemia (wAIHA). The 30 mg/kg dosing cohort showed a mean hemoglobin rise of 1 g/dL by week 1, with two‑thirds of patients...
SonoThera Bags $125M Series B to Advance Safer Gene Therapies
San Francisco‑based SonoThera announced a $125 million Series B round to fund its non‑viral gene‑therapy platform. The capital will accelerate lead programs for Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease into clinical trials and expand the pipeline to other organs....
Novartis Reports the Biomarker Data From P-I/II (FORTITUDE) Study of Del-Brax in FSHD
Novartis announced that its Phase I/II FORTITUDE study of delpacibart braxlosiran (del‑brax) met its primary biomarker endpoint and a key secondary endpoint in 90 patients with facioscapulohumeral muscular dystrophy (FSHD). The drug, given at 2 mg/kg every six weeks, significantly lowered...
How Basket-Trials Are Reshaping Drug Development Timelines
Basket trials, once confined to oncology, are being adapted for rare disease drug development as FDA guidance embraces Bayesian and external data. Polaryx’s chief medical officer explains that the approach consolidates recruitment across specialist centers, enabling simultaneous testing of multiple...
XtalPi Enters $400m Partnership for Small Molecule Therapy for GPCR Target
XtalPi announced a strategic partnership worth over $400 million with an international biopharma firm to develop oral small‑molecule therapeutics for a challenging G‑protein‑coupled receptor (GPCR). The deal follows a pilot phase where XtalPi’s quantum‑physics‑driven AI platform boosted hit rates against the...
Genentech’s Tecentriq Receives the US FDA Priority Review for Stage III dMMR/MSI-H Colon Cancer
Genentech’s checkpoint inhibitor Tecentriq (atezolizumab) and its hyaluronidase‑enhanced formulation Tecentriq Hybreza have received FDA acceptance of a supplemental BLA and priority review for use as adjuvant therapy with chemotherapy in stage III dMMR/MSI‑H colon cancer. The decision follows the Phase III ATOMIC...
GlycoNex Reports the P-III Trial Data on SPD8 (Biosimilar, Denosumab)
GlycoNex announced that its denosumab biosimilar SPD8 met the primary endpoint in a Phase III trial involving 266 Japanese osteoporosis patients, demonstrating therapeutic equivalence to Amgen’s Prolia. The study’s 95% confidence interval fell within pre‑specified equivalence margins, confirming comparable efficacy and...
Biotech AI Strategy: Why Most Pharma AI Projects Fail & How to Fix It? ( ft.Rose LaRocca-Fisch)
In this episode, Steve Swan talks with Rose LaRocca‑Fish, a veteran biotech CIO, about why most AI initiatives in pharma fail and how to set them up for success. Rose outlines her OASIS framework—Operating Alignment for Scalable Impact and Sustainability—emphasizing...
Once-Weekly Survodutide Linked to Drop in Body Weight in Obesity
A phase‑III trial published in the New England Journal of Medicine found that once‑weekly survodutide, a dual glucagon‑receptor/GLP‑1‑receptor agonist, produced substantial weight loss in adults with obesity and no diabetes. Over 76 weeks, participants receiving 3.6 mg lost 12.2% of body...
Pinnacle: Designing Oral Peptides to Close the Gap with Injectable Biologics
Pinnacle Therapeutics is advancing an oral peptide candidate for chronic obstructive pulmonary disease (COPD) with a goal of entering the clinic by the end of 2026. The effort is powered by an $89 million Series B round announced in March, which backs...
Antibody-Guided Nanoparticles Target Blood Cancer Cells in Bone Marrow
Researchers at Indiana University School of Medicine and Purdue University have engineered lipid nanoparticles conjugated with a BCMA‑specific antibody to deliver therapeutics directly to multiple myeloma cells in the bone marrow. In mouse models, the antibody‑guided nanoparticles achieved precise targeting...
Rare IL‑10 Autoantibody Subset May Respond to CAR‑T
Not every day you see an odds ratio of 50 (for interleukin-10 autoantibodies and a common HLA allele). ~80% of patients with inflammatory bowel disease (IBD) have this HLA allele These individuals (~3.5% of IBD) may benefit from B cell depletion...
WGS Uncovers Missed Clinically Relevant MDS Biomarkers
Whole Genome Sequencing [WGS] Reveals Novel, Clinically Relevant Biomarkers Missed by Standards of Care for Pts w/ Myelodysplastic Syndrome [MDS] [Jun 11, 2026] @AlexBataller et al. #EHA2026 EHA-4897 https://t.co/Je6wyHzypT #MDSsm #leusm #cagenome @UTMDAnderson @TempusAI
DNA Tetrahedrons Unlock Sharper Cancer Targeting with Vitamin E Tweak
Researchers at IIT Gandhinagar engineered DNA tetrahedron nanostructures by attaching alpha‑tocopherol succinate, a vitamin E derivative, to improve cancer cell targeting. The αT‑conjugated tetrahedrons showed markedly higher cellular uptake and induced reactive‑oxygen‑species‑mediated apoptosis in cancer cells while sparing healthy cells. Experiments...
SonoThera's Full-Length Dystrophin Therapy Hailed as Holy Grail
“This is really the Holy Grail,” one observer says of SonoThera’s full-length dystrophin therapy for Duchenne muscular dystrophy. Excited about the WSJ exclusive. https://t.co/5tJWnE4PFo via @WSJ
Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability...
In September 2010 the FDA issued final regulations under 21 CFR part 312 and part 320 that overhaul safety reporting for investigational new drug (IND) applications and bioavailability/bioequivalence (BA/BE) studies. The rule establishes precise definitions, reporting timelines, and criteria for what constitutes a meaningful...
Sanofi Halts Immune Drug Trial Amid Setback
Sanofi stops immune drug trial in latest research setback https://t.co/DO7ttZF838 by Kristin Jensen $DNTH - 10% $ARGX $SNY - 2%
In Silico Devices May Improve Drug Manufacturability
BigHat Biosciences highlighted at PEGS Boston that in silico models built on cell‑free expression can predict antibody yields, allowing researchers to explore far more mutations than traditional CHO cell assays. By coupling computational predictions with physical experiments, companies can prioritize...
Updated Amplification Tool Rapidly Detects Mycoplasma
Chinese researchers have unveiled a multiplex nucleic acid amplification test (NAAT) that slashes Mycoplasma testing time from the traditional 28‑day culture to just several hours. The assay targets three conserved regions, covering 183 Mollicutes species with single‑copy detection sensitivity and...
Other News to Note for June 10, 2026
BioWorld’s June 10 briefing highlights three breakthrough drug‑discovery programs. Skape Bio announced a de novo‑designed miniprotein platform that can engage hard‑to‑target GPCR binding pockets, opening new therapeutic avenues. Antares Therapeutics disclosed a series of potent CDK2/cyclin E1 inhibitors aimed at halting tumor...
Linerixibat
Linerixibat (brand name Lynavoy®), an oral ASBT/IBAT inhibitor, received FDA approval in March 2026 for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC). The drug works by blocking ileal bile‑acid reuptake, addressing the bile‑acid dysregulation that drives severe itching....
STAT+: Hope for Kendall Square’s Lab Market
Sanofi announced it is halting the Phase 3 trial of riliprubart after an interim analysis showed no efficacy, marking a setback for the French firm’s rare‑autoimmune pipeline. Meanwhile, Parabilis Medicines completed a $670 million IPO, the largest biotech offering to date, eclipsing...
Enhance Clinical Trial Screening and Improve Patient Matching Accuracy
Paradigm Health introduced a Clinical Trial Matching solution that merges structured patient data with large language models to enhance eligibility screening. The AI‑driven platform not only improves match accuracy by interpreting unstructured clinical notes but also provides transparent, natural‑language explanations...
Alzheimer’s Drug Review Sparks Expert Dispute over Benefits
Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness By @PamBelluck "The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments..." https://t.co/xjPGVCwtja
Coya Therapeutics CEO on ALS Urgency and Fast-Tracking COYA 302 for Patient Impact
Coya Therapeutics received FDA fast‑track designation for its ALS candidate COYA 302, an immune‑modulating combo of low‑dose IL‑2 and CTLA4‑Ig. The company plans to finish enrollment in the ALSTARS trial by late 2026, start a Phase IIa study in frontotemporal dementia, and...
Sustainability in Asthma and COPD Drug Development with Chiesi’s Diego Ardigò — Episode 259
Chiesi’s Executive Vice President Diego Ardigò discussed on the Xtalks Life Science Podcast how respiratory drug development must integrate formulation, device design, and patient experience. He highlighted the growing pressure to make inhalers more environmentally sustainable while preserving therapeutic continuity...
Lilly Wins New FDA Approval for Eczema Drug Ebglyss
Eli Lilly’s anti‑IL‑13 antibody Ebglyss received FDA clearance for a new maintenance regimen that reduces injections to six per year, shifting from bi‑weekly to every‑eight‑weeks dosing after induction. The label expansion positions Ebglyss against Dupixent and Adbry, which require more frequent...
Sanofi Cans Late-Stage Study for Rare Autoimmune Disease on Underwhelming Efficacy
Sanofi has halted the Phase 3 MOBILIZE trial of its complement inhibitor riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) after an independent data‑monitoring board deemed the interim results unlikely to demonstrate sufficient efficacy. The study, which enrolled roughly 140 patients and...
Amid a Flurry of Biotech Deals, China Looks to Keep Innovation at Home
China’s new Order 818, dubbed the "tech track," launched on May 1 to fast‑track cell, gene and regenerative therapies outside the traditional drug‑approval process. The pathway lets qualifying treatments skip three‑phase trials after meeting safety and preliminary‑efficacy thresholds, provided they partner with...
Disc’s FDA Meeting Sets ‘Clear Path’ for Embattled Rare Blood Disease Drug
Disc Medicine has secured an FDA agreement to resubmit its rare‑blood‑disorder drug bitopertin using data from the ongoing Phase 3 APOLLO trial. The agency previously rejected the drug in February 2026 over concerns that the surrogate endpoint did not reliably predict...
The State of Biologics Testing Report 2026
Charles River released the 2026 State of Biologics Testing report, highlighting a sector‑wide shift from legacy compendial assays toward advanced digital platforms, risk‑based strategies, and animal‑reduction techniques. The study, built on global testing data and interviews with biopharma, quality and...
Bayer's Asundexian Starts EU Review for Ischaemic Stroke
Bayer’s oral Factor XIa inhibitor asundexian has entered the European Medicines Agency’s review for secondary prevention of ischemic stroke, following the OCEANIC‑STROKE trial. The study showed a 26% relative reduction in recurrent stroke when added to standard antiplatelet therapy, without raising...
AbbVie's Migraine Drug Cleared for Migraine Attacks on NHS
AbbVie’s oral CGRP inhibitor Aquipta (atogepant) has received NHS commissioning approval in England and Wales for acute migraine treatment, extending its existing preventive use. NICE’s final draft guidance clears the drug for patients who have failed two triptans or cannot...
Oncolys BioPharma Reports MHLW Approval of Telomelysin for Esophageal Cancer
Oncolys BioPharma announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted full marketing approval for Telomelysin Injection (suratadenoturev/OBP‑301) to treat esophageal cancer patients who cannot undergo curative surgery or chemotherapy. The approval stems from a pivotal trial...
Lilly Tees Off with Novo at ADA, GSK’s $10.6B Deal, FDA Reform Continues in Makary’s Absence
Eli Lilly dominated the American Diabetes Association meeting with positive data on its new obesity pill Foundayo and the multi‑indication candidate retatrutide, showing benefits for weight loss, sleep apnea, knee pain and menopause. Novo Nordisk used the same forum to present expanded...
Why Insulin Never Reaches the Liver
The episode explores why injected insulin never reaches the liver, tracing the discovery to a pioneering study where a radioactive insulin tracer was found throughout rat bodies except the liver. This finding spurred the host's father, a liver‑targeted insulin delivery...
First Reverse‑aging Drug Administered to Human
The first-ever reverse-aging drug was just injected into a human Featuring @lifebiosciences @M_S_Ringel and @davidasinclair, with interviews by Daniel Oliver @rejuvenatebio, @mkaeberlein, @BKennedy_aging, and many more.👨⚕️ By @Hilarx @BusinessInsider🗞️ https://t.co/vdxr1geDzM https://t.co/sL2Ts1IjPA
Sanofi Abandons Phase 3 Trial of Neurology Drug Riliprubart
Sanofi has halted the phase 3 MOBILIZE trial of its C1s‑targeting antibody riliprubart for chronic inflammatory demyelinating polyneuropathy (CIDP) after an interim analysis deemed the drug unlikely to achieve sufficient efficacy. The study, which enrolled about 140 patients who were refractory...
Windward Bio Doses First Patients in Phase II SIRIUS COPD Trial
Harbour BioMed’s partner Windward Bio has begun dosing the first patients in the Phase II SIRIUS trial of HBM9378/WIN378, a fully human monoclonal antibody targeting TSLP for chronic obstructive pulmonary disease (COPD). The global, double‑blind, placebo‑controlled study will evaluate safety, tolerability,...
SpinaFX Receives the US FDA IDE Approval to Initiate Trial for Triojection Therapy
SpinaFX has secured an FDA Investigational Device Exemption (IDE) to launch a U.S. trial of its Triojection therapy, a minimally invasive, image‑guided treatment for patients with contained lumbar disc herniations unresponsive to conservative care. The randomized study will enroll roughly...